WO2018164507A2 - Mast4 유전자를 이용한 세포외 기질 생산용 조성물 및 그 제조방법 - Google Patents
Mast4 유전자를 이용한 세포외 기질 생산용 조성물 및 그 제조방법 Download PDFInfo
- Publication number
- WO2018164507A2 WO2018164507A2 PCT/KR2018/002763 KR2018002763W WO2018164507A2 WO 2018164507 A2 WO2018164507 A2 WO 2018164507A2 KR 2018002763 W KR2018002763 W KR 2018002763W WO 2018164507 A2 WO2018164507 A2 WO 2018164507A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- mast4
- composition
- fragment
- protein
- extracellular matrix
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 63
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 title claims abstract description 62
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 title claims abstract description 62
- 210000002744 extracellular matrix Anatomy 0.000 title claims abstract description 62
- 108090000623 proteins and genes Proteins 0.000 title claims abstract description 37
- 238000002360 preparation method Methods 0.000 title description 4
- 101001018298 Homo sapiens Microtubule-associated serine/threonine-protein kinase 4 Proteins 0.000 claims abstract description 151
- 102100033252 Microtubule-associated serine/threonine-protein kinase 4 Human genes 0.000 claims abstract description 150
- 210000003527 eukaryotic cell Anatomy 0.000 claims abstract description 47
- 239000012634 fragment Substances 0.000 claims abstract description 36
- 230000001737 promoting effect Effects 0.000 claims abstract description 29
- 102000039446 nucleic acids Human genes 0.000 claims abstract description 28
- 108020004707 nucleic acids Proteins 0.000 claims abstract description 28
- 150000007523 nucleic acids Chemical class 0.000 claims abstract description 28
- 150000001875 compounds Chemical class 0.000 claims abstract description 24
- 108091033319 polynucleotide Proteins 0.000 claims abstract description 21
- 102000040430 polynucleotide Human genes 0.000 claims abstract description 21
- 239000002157 polynucleotide Substances 0.000 claims abstract description 21
- 102000004169 proteins and genes Human genes 0.000 claims abstract description 17
- 229920001184 polypeptide Polymers 0.000 claims abstract description 10
- 102000004196 processed proteins & peptides Human genes 0.000 claims abstract description 10
- 108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 10
- 230000003848 cartilage regeneration Effects 0.000 claims abstract description 7
- 230000014509 gene expression Effects 0.000 claims description 48
- 210000001612 chondrocyte Anatomy 0.000 claims description 30
- 238000004519 manufacturing process Methods 0.000 claims description 29
- 238000000034 method Methods 0.000 claims description 27
- 230000022159 cartilage development Effects 0.000 claims description 22
- 108020005004 Guide RNA Proteins 0.000 claims description 20
- 150000001413 amino acids Chemical group 0.000 claims description 20
- 230000000694 effects Effects 0.000 claims description 19
- 239000004055 small Interfering RNA Substances 0.000 claims description 19
- 102000046299 Transforming Growth Factor beta1 Human genes 0.000 claims description 12
- 101800002279 Transforming growth factor beta-1 Proteins 0.000 claims description 12
- 108020004459 Small interfering RNA Proteins 0.000 claims description 11
- 108091079001 CRISPR RNA Proteins 0.000 claims description 10
- 108091028113 Trans-activating crRNA Proteins 0.000 claims description 10
- 238000012258 culturing Methods 0.000 claims description 9
- 208000012659 Joint disease Diseases 0.000 claims description 6
- 239000000126 substance Substances 0.000 claims description 5
- 230000017423 tissue regeneration Effects 0.000 claims description 5
- 108091007412 Piwi-interacting RNA Proteins 0.000 claims description 4
- 102000039471 Small Nuclear RNA Human genes 0.000 claims description 4
- 108091027967 Small hairpin RNA Proteins 0.000 claims description 4
- 230000032683 aging Effects 0.000 claims description 4
- 239000000427 antigen Substances 0.000 claims description 4
- 102000036639 antigens Human genes 0.000 claims description 4
- 108091007433 antigens Proteins 0.000 claims description 4
- 210000002950 fibroblast Anatomy 0.000 claims description 4
- 239000002679 microRNA Substances 0.000 claims description 4
- 108700011259 MicroRNAs Proteins 0.000 claims description 3
- 108091029842 small nuclear ribonucleic acid Proteins 0.000 claims description 3
- 208000024891 symptom Diseases 0.000 claims description 3
- 108020000948 Antisense Oligonucleotides Proteins 0.000 claims 1
- 239000000074 antisense oligonucleotide Substances 0.000 claims 1
- 238000012230 antisense oligonucleotides Methods 0.000 claims 1
- 210000004027 cell Anatomy 0.000 description 46
- 108091033409 CRISPR Proteins 0.000 description 43
- 210000000845 cartilage Anatomy 0.000 description 31
- 238000010354 CRISPR gene editing Methods 0.000 description 23
- 238000011813 knockout mouse model Methods 0.000 description 19
- 239000002773 nucleotide Substances 0.000 description 16
- 125000003729 nucleotide group Chemical group 0.000 description 16
- 241000282414 Homo sapiens Species 0.000 description 11
- 239000013612 plasmid Substances 0.000 description 11
- 238000003757 reverse transcription PCR Methods 0.000 description 11
- 108020004414 DNA Proteins 0.000 description 10
- 241000699670 Mus sp. Species 0.000 description 10
- 210000001519 tissue Anatomy 0.000 description 10
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 8
- 241000700605 Viruses Species 0.000 description 7
- 230000008859 change Effects 0.000 description 7
- 210000005260 human cell Anatomy 0.000 description 7
- VZSRBBMJRBPUNF-UHFFFAOYSA-N 2-(2,3-dihydro-1H-inden-2-ylamino)-N-[3-oxo-3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)propyl]pyrimidine-5-carboxamide Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)C(=O)NCCC(N1CC2=C(CC1)NN=N2)=O VZSRBBMJRBPUNF-UHFFFAOYSA-N 0.000 description 6
- 101100400483 Homo sapiens MAST4 gene Proteins 0.000 description 6
- 241000699666 Mus <mouse, genus> Species 0.000 description 6
- 108020004999 messenger RNA Proteins 0.000 description 6
- 210000002303 tibia Anatomy 0.000 description 6
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 5
- 238000003559 RNA-seq method Methods 0.000 description 5
- 238000012790 confirmation Methods 0.000 description 5
- 239000003112 inhibitor Substances 0.000 description 5
- 239000002953 phosphate buffered saline Substances 0.000 description 5
- 238000003752 polymerase chain reaction Methods 0.000 description 5
- 230000002441 reversible effect Effects 0.000 description 5
- 150000003839 salts Chemical class 0.000 description 5
- 230000008685 targeting Effects 0.000 description 5
- 108091027544 Subgenomic mRNA Proteins 0.000 description 4
- 101150063416 add gene Proteins 0.000 description 4
- 230000000295 complement effect Effects 0.000 description 4
- 230000004069 differentiation Effects 0.000 description 4
- 210000002257 embryonic structure Anatomy 0.000 description 4
- 230000002401 inhibitory effect Effects 0.000 description 4
- 230000001404 mediated effect Effects 0.000 description 4
- 239000000546 pharmaceutical excipient Substances 0.000 description 4
- 230000002829 reductive effect Effects 0.000 description 4
- 238000001890 transfection Methods 0.000 description 4
- WZFUQSJFWNHZHM-UHFFFAOYSA-N 2-[4-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]piperazin-1-yl]-1-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)ethanone Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)N1CCN(CC1)CC(=O)N1CC2=C(CC1)NN=N2 WZFUQSJFWNHZHM-UHFFFAOYSA-N 0.000 description 3
- YLZOPXRUQYQQID-UHFFFAOYSA-N 3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)-1-[4-[2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidin-5-yl]piperazin-1-yl]propan-1-one Chemical compound N1N=NC=2CN(CCC=21)CCC(=O)N1CCN(CC1)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F YLZOPXRUQYQQID-UHFFFAOYSA-N 0.000 description 3
- 101150091111 ACAN gene Proteins 0.000 description 3
- 102100024506 Bone morphogenetic protein 2 Human genes 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 101000762366 Homo sapiens Bone morphogenetic protein 2 Proteins 0.000 description 3
- 101100400484 Mus musculus Mast4 gene Proteins 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 210000003321 cartilage cell Anatomy 0.000 description 3
- 238000010276 construction Methods 0.000 description 3
- 239000002537 cosmetic Substances 0.000 description 3
- 238000012217 deletion Methods 0.000 description 3
- 230000037430 deletion Effects 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 230000005764 inhibitory process Effects 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 238000010172 mouse model Methods 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 238000011069 regeneration method Methods 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 239000000758 substrate Substances 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 239000012096 transfection reagent Substances 0.000 description 3
- 241000283690 Bos taurus Species 0.000 description 2
- 101150082216 COL2A1 gene Proteins 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- 241000282693 Cercopithecidae Species 0.000 description 2
- 102000008186 Collagen Human genes 0.000 description 2
- 108010035532 Collagen Proteins 0.000 description 2
- 102000053602 DNA Human genes 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- 102100031780 Endonuclease Human genes 0.000 description 2
- 241000283086 Equidae Species 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- 229930182566 Gentamicin Natural products 0.000 description 2
- CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 description 2
- WZUVPPKBWHMQCE-UHFFFAOYSA-N Haematoxylin Chemical compound C12=CC(O)=C(O)C=C2CC2(O)C1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-UHFFFAOYSA-N 0.000 description 2
- 108060003951 Immunoglobulin Proteins 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- 108010077850 Nuclear Localization Signals Proteins 0.000 description 2
- 229930040373 Paraformaldehyde Natural products 0.000 description 2
- 108091000080 Phosphotransferase Proteins 0.000 description 2
- 102000001708 Protein Isoforms Human genes 0.000 description 2
- 108010029485 Protein Isoforms Proteins 0.000 description 2
- 241000194017 Streptococcus Species 0.000 description 2
- 230000003712 anti-aging effect Effects 0.000 description 2
- 230000000890 antigenic effect Effects 0.000 description 2
- 239000003125 aqueous solvent Substances 0.000 description 2
- 235000014121 butter Nutrition 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 229920001436 collagen Polymers 0.000 description 2
- 239000002299 complementary DNA Substances 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 239000003937 drug carrier Substances 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 239000000945 filler Substances 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 230000037433 frameshift Effects 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 230000002068 genetic effect Effects 0.000 description 2
- 238000010362 genome editing Methods 0.000 description 2
- 229960002518 gentamicin Drugs 0.000 description 2
- 102000018358 immunoglobulin Human genes 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 244000005700 microbiome Species 0.000 description 2
- 238000000520 microinjection Methods 0.000 description 2
- 229920002866 paraformaldehyde Polymers 0.000 description 2
- -1 phosphoroester Chemical compound 0.000 description 2
- 102000020233 phosphotransferase Human genes 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- RXWNCPJZOCPEPQ-NVWDDTSBSA-N puromycin Chemical compound C1=CC(OC)=CC=C1C[C@H](N)C(=O)N[C@H]1[C@@H](O)[C@H](N2C3=NC=NC(=C3N=C2)N(C)C)O[C@@H]1CO RXWNCPJZOCPEPQ-NVWDDTSBSA-N 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 238000012163 sequencing technique Methods 0.000 description 2
- UNFWWIHTNXNPBV-WXKVUWSESA-N spectinomycin Chemical compound O([C@@H]1[C@@H](NC)[C@@H](O)[C@H]([C@@H]([C@H]1O1)O)NC)[C@]2(O)[C@H]1O[C@H](C)CC2=O UNFWWIHTNXNPBV-WXKVUWSESA-N 0.000 description 2
- 238000010186 staining Methods 0.000 description 2
- 239000000829 suppository Substances 0.000 description 2
- 239000000080 wetting agent Substances 0.000 description 2
- GUAHPAJOXVYFON-ZETCQYMHSA-N (8S)-8-amino-7-oxononanoic acid zwitterion Chemical compound C[C@H](N)C(=O)CCCCCC(O)=O GUAHPAJOXVYFON-ZETCQYMHSA-N 0.000 description 1
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 1
- OHVLMTFVQDZYHP-UHFFFAOYSA-N 1-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)-2-[4-[2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidin-5-yl]piperazin-1-yl]ethanone Chemical compound N1N=NC=2CN(CCC=21)C(CN1CCN(CC1)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F)=O OHVLMTFVQDZYHP-UHFFFAOYSA-N 0.000 description 1
- HMUNWXXNJPVALC-UHFFFAOYSA-N 1-[4-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]piperazin-1-yl]-2-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)ethanone Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)N1CCN(CC1)C(CN1CC2=C(CC1)NN=N2)=O HMUNWXXNJPVALC-UHFFFAOYSA-N 0.000 description 1
- LDXJRKWFNNFDSA-UHFFFAOYSA-N 2-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)-1-[4-[2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidin-5-yl]piperazin-1-yl]ethanone Chemical compound C1CN(CC2=NNN=C21)CC(=O)N3CCN(CC3)C4=CN=C(N=C4)NCC5=CC(=CC=C5)OC(F)(F)F LDXJRKWFNNFDSA-UHFFFAOYSA-N 0.000 description 1
- FJCDSQATIJKQKA-UHFFFAOYSA-N 2-fluoro-n-[[5-(6-methylpyridin-2-yl)-4-([1,2,4]triazolo[1,5-a]pyridin-6-yl)-1h-imidazol-2-yl]methyl]aniline Chemical compound CC1=CC=CC(C2=C(N=C(CNC=3C(=CC=CC=3)F)N2)C2=CN3N=CN=C3C=C2)=N1 FJCDSQATIJKQKA-UHFFFAOYSA-N 0.000 description 1
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 1
- CKLBXIYTBHXJEH-UHFFFAOYSA-J 75881-23-1 Chemical compound [Cl-].[Cl-].[Cl-].[Cl-].[Cu+2].[N-]1C(N=C2C3=CC=C(CSC(N(C)C)=[N+](C)C)C=C3C(N=C3C4=CC=C(CSC(N(C)C)=[N+](C)C)C=C4C(=N4)[N-]3)=N2)=C(C=C(CSC(N(C)C)=[N+](C)C)C=C2)C2=C1N=C1C2=CC(CSC(N(C)C)=[N+](C)C)=CC=C2C4=N1 CKLBXIYTBHXJEH-UHFFFAOYSA-J 0.000 description 1
- 102000016284 Aggrecans Human genes 0.000 description 1
- 108010067219 Aggrecans Proteins 0.000 description 1
- 239000012099 Alexa Fluor family Substances 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 241000203069 Archaea Species 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 108091028026 C-DNA Proteins 0.000 description 1
- 101150057175 COL9A1 gene Proteins 0.000 description 1
- 240000001432 Calendula officinalis Species 0.000 description 1
- 235000005881 Calendula officinalis Nutrition 0.000 description 1
- KXDHJXZQYSOELW-UHFFFAOYSA-M Carbamate Chemical compound NC([O-])=O KXDHJXZQYSOELW-UHFFFAOYSA-M 0.000 description 1
- 102000012422 Collagen Type I Human genes 0.000 description 1
- 108010022452 Collagen Type I Proteins 0.000 description 1
- 108020004635 Complementary DNA Proteins 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 1
- 108010042407 Endonucleases Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 1
- 239000004606 Fillers/Extenders Substances 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 241000238631 Hexapoda Species 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101001059454 Homo sapiens Serine/threonine-protein kinase MARK2 Proteins 0.000 description 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
- 229930182816 L-glutamine Natural products 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 239000012098 Lipofectamine RNAiMAX Substances 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 229920001410 Microfiber Polymers 0.000 description 1
- 108010020004 Microtubule-Associated Proteins Proteins 0.000 description 1
- 102000009664 Microtubule-Associated Proteins Human genes 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- 241000699660 Mus musculus Species 0.000 description 1
- AFCARXCZXQIEQB-UHFFFAOYSA-N N-[3-oxo-3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)propyl]-2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidine-5-carboxamide Chemical compound O=C(CCNC(=O)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F)N1CC2=C(CC1)NN=N2 AFCARXCZXQIEQB-UHFFFAOYSA-N 0.000 description 1
- 101710163270 Nuclease Proteins 0.000 description 1
- 108091034117 Oligonucleotide Proteins 0.000 description 1
- 239000012124 Opti-MEM Substances 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 102000001253 Protein Kinase Human genes 0.000 description 1
- 238000010802 RNA extraction kit Methods 0.000 description 1
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 1
- 108091028664 Ribonucleotide Proteins 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 238000012300 Sequence Analysis Methods 0.000 description 1
- 102100028904 Serine/threonine-protein kinase MARK2 Human genes 0.000 description 1
- 108020004688 Small Nuclear RNA Proteins 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 241000193996 Streptococcus pyogenes Species 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- 244000299461 Theobroma cacao Species 0.000 description 1
- 235000005764 Theobroma cacao ssp. cacao Nutrition 0.000 description 1
- 235000005767 Theobroma cacao ssp. sphaerocarpum Nutrition 0.000 description 1
- 206010052428 Wound Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000000692 anti-sense effect Effects 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 210000001188 articular cartilage Anatomy 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000033558 biomineral tissue development Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 235000001046 cacaotero Nutrition 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 230000002648 chondrogenic effect Effects 0.000 description 1
- 208000037976 chronic inflammation Diseases 0.000 description 1
- 230000006020 chronic inflammation Effects 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000012937 correction Methods 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000000593 degrading effect Effects 0.000 description 1
- 239000005547 deoxyribonucleotide Substances 0.000 description 1
- 125000002637 deoxyribonucleotide group Chemical group 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- NAGJZTKCGNOGPW-UHFFFAOYSA-K dioxido-sulfanylidene-sulfido-$l^{5}-phosphane Chemical compound [O-]P([O-])([S-])=S NAGJZTKCGNOGPW-UHFFFAOYSA-K 0.000 description 1
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000000428 dust Substances 0.000 description 1
- 238000004520 electroporation Methods 0.000 description 1
- YQGOJNYOYNNSMM-UHFFFAOYSA-N eosin Chemical compound [Na+].OC(=O)C1=CC=CC=C1C1=C2C=C(Br)C(=O)C(Br)=C2OC2=C(Br)C(O)=C(Br)C=C21 YQGOJNYOYNNSMM-UHFFFAOYSA-N 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
- 229940093471 ethyl oleate Drugs 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000013604 expression vector Substances 0.000 description 1
- 230000035558 fertility Effects 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 238000012757 fluorescence staining Methods 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 239000012737 fresh medium Substances 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 238000003208 gene overexpression Methods 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 208000024908 graft versus host disease Diseases 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 238000003306 harvesting Methods 0.000 description 1
- 238000009396 hybridization Methods 0.000 description 1
- 230000000521 hyperimmunizing effect Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- VMPHSYLJUKZBJJ-UHFFFAOYSA-N lauric acid triglyceride Natural products CCCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCC)COC(=O)CCCCCCCCCCC VMPHSYLJUKZBJJ-UHFFFAOYSA-N 0.000 description 1
- 238000001638 lipofection Methods 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 229940057995 liquid paraffin Drugs 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 229960003511 macrogol Drugs 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 230000013011 mating Effects 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000011987 methylation Effects 0.000 description 1
- 238000007069 methylation reaction Methods 0.000 description 1
- YACKEPLHDIMKIO-UHFFFAOYSA-N methylphosphonic acid Chemical compound CP(O)(O)=O YACKEPLHDIMKIO-UHFFFAOYSA-N 0.000 description 1
- 108091070501 miRNA Proteins 0.000 description 1
- 239000003658 microfiber Substances 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 239000002105 nanoparticle Substances 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 230000011164 ossification Effects 0.000 description 1
- 210000003101 oviduct Anatomy 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- PTMHPRAIXMAOOB-UHFFFAOYSA-L phosphoramidate Chemical compound NP([O-])([O-])=O PTMHPRAIXMAOOB-UHFFFAOYSA-L 0.000 description 1
- 230000026731 phosphorylation Effects 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000037452 priming Effects 0.000 description 1
- 230000004952 protein activity Effects 0.000 description 1
- 108060006633 protein kinase Proteins 0.000 description 1
- 230000005180 public health Effects 0.000 description 1
- 229950010131 puromycin Drugs 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000001172 regenerating effect Effects 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 239000002336 ribonucleotide Substances 0.000 description 1
- 125000002652 ribonucleotide group Chemical group 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 229960004509 serum gonadotrophin Drugs 0.000 description 1
- 230000007727 signaling mechanism Effects 0.000 description 1
- 230000012488 skeletal system development Effects 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- RYYWUUFWQRZTIU-UHFFFAOYSA-K thiophosphate Chemical compound [O-]P([O-])([O-])=S RYYWUUFWQRZTIU-UHFFFAOYSA-K 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 108700026220 vif Genes Proteins 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
- A01K67/027—New or modified breeds of vertebrates
- A01K67/0275—Genetically modified vertebrates, e.g. transgenic
- A01K67/0278—Knock-in vertebrates, e.g. humanised vertebrates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y207/00—Transferases transferring phosphorus-containing groups (2.7)
- C12Y207/11—Protein-serine/threonine kinases (2.7.11)
- C12Y207/11001—Non-specific serine/threonine protein kinase (2.7.11.1), i.e. casein kinase or checkpoint kinase
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/07—Animals genetically altered by homologous recombination
- A01K2217/075—Animals genetically altered by homologous recombination inducing loss of function, i.e. knock out
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2227/00—Animals characterised by species
- A01K2227/10—Mammal
- A01K2227/105—Murine
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2267/00—Animals characterised by purpose
- A01K2267/03—Animal model, e.g. for test or diseases
- A01K2267/035—Animal model for multifactorial diseases
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/14—Type of nucleic acid interfering N.A.
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/20—Type of nucleic acid involving clustered regularly interspaced short palindromic repeats [CRISPRs]
Definitions
- the present invention is a composition for producing extracellular matrix from eukaryotic cells using MAST4 (Microtubule Associated Serine / Threonine Kinase Family Member 4) gene, a method for producing extracellular matrix from eukaryotic cells and cartilage regeneration comprising the composition It relates to a composition for promotion.
- MAST4 Microtubule Associated Serine / Threonine Kinase Family Member 4
- MAST Microtubule associated serine / threonine kinase 4 is known to be expressed in cartilage ( BMC Genomics 2007, 8: 165), its role is not clearly identified. Although CN 105636614 discloses the possibility of cartilage treatment with MAST4, it is based solely on the probabilistic results of MAST4 expression in cartilage and does not clarify its specific role.
- MAST4 as a novel central regulator involved in cartilage formation and provide a source technology for the development of substances that modulate the activity of MAST4.
- Non-Patent Document BMC Genomics 2007, 8: 165
- Patent Documents CN 105636614
- a compound capable of specifically binding to a MAST4 (Microtubule Associated Serine / Threonine Kinase Family Member 4) protein or a fragment thereof, or a compound capable of specifically binding to a nucleic acid encoding the MAST4 protein or a fragment thereof Provided is a composition for promoting the production of extracellular matrix in eukaryotic cells.
- MAST4 Microtubule Associated Serine / Threonine Kinase Family Member 4
- Another aspect is chondrogenesis from chondrocytes comprising a compound capable of specifically binding to a MAST4 protein or fragment thereof, or a compound capable of specifically binding to a nucleic acid encoding the MAST4 protein or fragment thereof. It provides a composition for promoting the.
- Another aspect provides a method of producing extracellular matrix from eukaryotic cells comprising contacting a composition for promoting extracellular matrix production from the eukaryotic cell with the eukaryotic cell.
- a compound capable of specifically binding to a MAST4 (Microtubule Associated Serine / Threonine Kinase Family Member 4) protein or a fragment thereof, or a compound capable of specifically binding to a nucleic acid encoding the MAST4 protein or a fragment thereof It provides a composition for promoting the production of extracellular matrix in the eukaryotic cell (extracellular matrix).
- MAST4 Microtubule Associated Serine / Threonine Kinase Family Member 4
- extracellular matrix extracellular matrix
- Chondrogenesis from chondrocytes comprising a compound capable of specifically binding to a MAST4 protein or fragment thereof, or a compound capable of specifically binding to a nucleic acid encoding the MAST4 protein or fragment thereof
- the present invention provides a composition for promoting).
- the compound capable of specifically binding to the MAST4 protein or fragment thereof, or the compound capable of specifically binding to a nucleic acid encoding the MAST4 protein or fragment thereof may comprise the protein or fragment thereof, or And capable of at least partially binding to a nucleic acid.
- the compound may be a chemically synthesized compound, polypeptide, polynucleotide, or a combination thereof. These may be ones that inhibit the activity or expression of the MAST4 protein.
- the composition for promoting the production of extracellular matrix in the eukaryotic cells may be a composition for promoting cartilage formation from eukaryotic cells.
- any of the inhibitors of the activity of the MAST4 protein or the inhibitor of the expression of the MAST4 protein is included as long as it inhibits the expression of the MAST4 gene or inhibits the activity of the MAST4 protein.
- the activity inhibitor or expression inhibitor may be a polynucleotide complementary to all or a portion of the MAST4 gene.
- the polynucleotide sequence may be RNA, DNA, or a fusion thereof.
- the inhibition of MAST4 protein activity may be to inhibit the kinase activity of MAST4 protein.
- MAST4 can phosphorylate Ser or Thr of a target substrate as a kinase
- inhibition of kinase activity of the MAST4 protein may mean blocking phosphorylation of a substrate targeted by MAST4, specifically, Ser or Thr. have.
- the polypeptide capable of specifically binding to the MAST4 protein or fragment thereof, or the polypeptide capable of specifically binding to a nucleic acid encoding the MAST4 protein or fragment thereof is an antibody, or antigen binding fragment thereof. Can be.
- antibody refers to a specific immunoglobulin directed against an antigenic site, wherein the MAST4 gene is cloned into an expression vector to obtain a MAST4 protein encoded by the gene, from the protein according to conventional methods in the art.
- Antibodies can be prepared. Forms of such antibodies include polyclonal antibodies or monoclonal antibodies, and include all immunoglobulin antibodies. The antibody does not have the structure of a full form intact antibody with two light chains and two heavy chains, as well as a full form with two full length light chains and two full length heavy chains, but is directed against antigenic sites Also included are functional fragments of antibody molecules that possess specific antigen binding sites (binding domains) and retain antigen binding function.
- polynucleotide may be used in the same sense as a nucleotide or nucleic acid, unless stated otherwise, and refers to deoxyribonucleotides or ribonucleotides, unless otherwise specified, analogs and sugars of natural nucleotides or The base moiety may comprise an analog modified.
- the polynucleotide can be modified through various methods known in the art as needed.
- modifications include methylation, capping, substitution of one or more homologs of natural nucleotides, and modifications between nucleotides, such as uncharged linkages such as methylphosphonate, phosphoroester, phosphoramidate, carbamate And the like) or a charged linker such as phosphorothioate, phosphorodithioate and the like.
- a compound capable of specifically binding to a nucleic acid encoding the MAST4 protein or fragment thereof is the MAST4 protein Or miRNAs (microRNA), siRNA (small interfering RNA), shRNA (short hairpin RNA), Piwi-interacting RNA (piRNA), snRNA (small nuclearRNA), antisense specific for nucleic acids encoding fragments thereof Oligonucleotides or combinations thereof.
- the compound capable of specifically binding to a nucleic acid encoding the MAST4 protein or fragment thereof comprises a polynucleotide capable of specifically binding to a nucleic acid encoding the MAST4 protein or fragment thereof.
- CRISPR-Cas comprising guide RNA specific for the nucleic acid encoding the MAST4 protein or fragment thereof.
- the Cas may be Cas9.
- CRISPRs Clustered Regularly Interspaced Short Palindromic Repeats
- guide RNA specifically, two RNAs, namely CRISPR RNA (crRNA) and trans-activating crRNA (tracrRNA) included in the guideRNA
- crRNA CRISPR RNA
- tracrRNA trans-activating crRNA
- the guide RNA comprises crRNA (CRISPR RNA) and tracrRNA (transactivating crRNA) specific for the nucleic acid encoding the MAST4 protein.
- CRISPR RNA crRNA
- tracrRNA transactivating crRNA
- Said double RNA and single-chain guide RNA can at least partially hybridize with the polynucleotide encoding the MAST4 protein, specifically "5'-TACCCTGCCGCTGCCGCACC-3 '(SEQ ID NO: 5) of the polynucleotide sequence encoding the amino acid sequence of the MAST4 protein. Hybridization with the part corresponding to number 17) ".
- the guide RNA hybridizes to a selected nucleotide sequence encoding the MAST4 protein, a dualRNA comprising a crRNA and a tracrRNA, or a portion of the crRNA and tracrRNA and hybridizes to a nucleotide encoding the MAST4 protein.
- the target sequence, the MAST4 gene comprises at least in part a sequence comprising a polynucleotide sequence of a sequence complementary to the crRNA or sgRNA and a protospacer-adjacent motif (PAM) do.
- the protopole fit motif may be one having a sequence well known to the nuclease protein as a sequence well known in the art.
- the MAST4 gene that is the target of the CRISPR-Cas system may be endogenous DNA or artificial DNA.
- the nucleotide encoding the MAST4 protein may be an endogenous DNA of eukaryotic cells, more specifically. May refer to the intrinsic DNA of chondrocytes.
- the crRNA or sgRNA may comprise 20 contiguous polynucleotides complementary to the target DNA, and the target DNA of the complementary 20 contiguous polynucleotides is 5'-TACCCTGCCGCTGCCGCACC-3 '( SEQ ID NO: 17), and may include a selection among the sequences shown in bold in SEQ ID NOs: 74, 76, and 77 in Table 6.
- the nucleic acid or Cas9 protein encoding the Cas9 protein may be derived from a genus Streptococcus microorganism. The microorganism of the genus Streptococcus may be streptococcus pyogenes.
- the PAM may mean a 5'-NGG-3 'trinucleotide, and the Cas9 protein may have a nuclear localization signal (NLS) at the C-terminus or the N-terminus to enhance efficiency. It may further include.
- NLS nuclear localization signal
- the eukaryotic cells are yeast, fungi, protozoa, plants, higher plants and insects, amphibian cells, or mammalian cells Can be.
- the mammal may be a variety of humans including monkeys, cows, horses, pigs and the like.
- Such eukaryotic cells include, but are not limited to, cells cultured (in vitro), transplanted cells, in vivo cells, or recombinant cells isolated from an individual.
- Eukaryotic cells isolated from the subject may be eukaryotic cells isolated from the same subject as the subject to which the product comprising the extracellular matrix produced from the eukaryotic cell is to be injected. In this case, there is an advantage that can prevent side effects such as unnecessary hyperimmune reactions or rejection reactions, including graft-versus-host reaction that can be generated by injection of products produced from different individuals.
- the eukaryotic cell may be fibroblast or chondrocyte.
- the composition for promoting the production of extracellular matrix in the eukaryotic cell and / or the composition for promoting chondrogenesis from chondrocytes may further comprise TGF- ⁇ 1.
- TGF- ⁇ 1 decreases the expression of MAST4 in human chondrocytes, thereby promoting the production of extracellular matrix.
- the MAST4 is a protein derived from human ( Homo sapiens ) or mouse ( Mus musculus), but the same protein may be expressed in other mammals such as monkeys, cows, and horses.
- Human-derived MAST4 may include all seven isoforms present in human cells.
- the seven isoforms are NP_055998.1 (SEQ ID NO: 1), N P_942123.1 (SEQ ID NO: 2), NP_001158136.1 (SEQ ID NO: 3), NP_001277155.1 (SEQ ID NO: 4), NP_001277156 based on the NCBI reference sequence.
- NP_001277157.1 (SEQ ID NO: 6), or NP_001284580.1 (SEQ ID NO: 7), wherein the protein or polypeptide having the respective amino acid sequence is NM_015183.2, A polynucleotide sequence of SEQ ID NOs: 8 to 14 encoding the amino acid sequence of each of SEQ ID NOs: 1 to 7 in the sequence of NM_198828.2, NM_001164664.1, NM_001290226.1, NM_001290227.1, NM_001290228.1, or NM_001297651.1 Each translated from the containing mRNA may be.
- MAST4 derived from a mouse may include an amino acid sequence of NP_780380.2 (SEQ ID NO: 15) based on an NCBI reference sequence, and the protein or polypeptide having the amino acid sequence may have an amino acid sequence of SEQ ID NO: 15 in the sequence of NM_175171.3. It may be translated from mRNA comprising the polynucleotide sequence of SEQ ID NO: 16 coding.
- an amino acid sequence or polynucleotide sequence having biologically equivalent activity may be considered a MAST4 protein or mRNA thereof have.
- the MAST4 protein comprises the sequence of any one of SEQ ID NOs: 1 to 7 and 15, the nucleotide sequence encoding the MAST4 protein comprises the sequence of any one of SEQ ID NOs: 8 to 14 and 16. It may be.
- the MAST4 protein or polypeptide has at least 60%, for example at least 70%, at least 80%, at least 90%, at least 95%, at least 99%, or 100% sequence identity with SEQ ID NOs: 1-7 and 15 It may include an amino acid sequence.
- the MAST4 protein is one or more amino acids, two or more amino acids, three or more amino acids, four or more amino acids, five or more amino acids, six or more amino acids, or seven or more amino acids in the amino acid sequences of SEQ ID NOs: 1 to 7 and 15.
- the amino acid may be an amino acid sequence having a changed sequence.
- the polynucleotide encoding each of the MAST4 is SEQ ID NO: 8 to 14 and 16 and 60% or more, for example, 70% or more, 80% or more, 90% or more, 95% or more, 99% or more, or 100% sequence It may be one having a sequence having identity.
- the nucleic acid encoding the MAST4 is at least one or more nucleotides, two or more nucleotides, three or more nucleotides, four or more nucleotides, five or more nucleotides in the sequence of SEQ ID NOs: 8 to 14 and 16
- the at least nucleotides or at least seven nucleotides may be polynucleotides having different sequences.
- the inventors first identified that inhibiting MAST4 gene expression in chondrocytes increases the production of extracellular matrix and promotes cartilage formation.
- the composition for promoting the production of extracellular matrix in the eukaryotic cells of the present invention or the composition for promoting cartilage formation from chondrocytes may be for the prevention, treatment or improvement of symptoms of joint disease. have.
- the composition for promoting the production of extracellular matrix in the eukaryotic cells of the present invention or a composition for promoting cartilage formation from chondrocytes may be to induce cartilage regeneration.
- the composition for promoting the production of extracellular matrix in the eukaryotic cells may be for use in preventing tissue regeneration or aging.
- the tissue regeneration refers to the regeneration of the skin damaged or modified by wounds, burns, trauma, aging, chronic inflammation, disease, genetic factors, etc., and includes both those used for medical or skin cosmetic purposes.
- the damage or modification is caused by the loss of the extracellular matrix in the tissue, reduced production or incapable of recovery by the above factors, and improves, alleviates, recovers by promoting the production of the extracellular matrix by the composition of the present invention. Or cure is possible.
- the composition of the present invention may increase the production of extracellular matrix, thereby preventing or promoting elasticity reduction, deformation, or damage of tissues due to aging.
- the tissue regeneration or anti-aging composition may be used as a filler, a component of collagen supplement cosmetics. In another embodiment, the tissue regeneration or anti-aging composition may be used as a component of the functional cosmetics to block the adsorption of fine dust or minerals.
- composition for promoting the production of extracellular matrix in the eukaryotic cells of the present invention or the composition for promoting cartilage formation from chondrocytes may further comprise a pharmaceutically acceptable salt or carrier.
- pharmaceutically acceptable salts means any of the compounds in the compositions of the present invention that are relatively nontoxic to the patient and have a harmless effective action and that the side effects caused by these salts do not compromise the beneficial efficacy of the compositions of the present invention. It means an organic or inorganic addition salt. These salts can be selected any known to those skilled in the art.
- composition of the present invention may further comprise a pharmaceutically acceptable carrier.
- the composition comprising a pharmaceutically acceptable carrier can be in various oral or parenteral formulations. When formulated, it may be prepared using diluents or excipients such as fillers, extenders, binders, wetting agents, disintegrating agents, surfactants, etc. which are commonly used. Solid preparations for oral administration may include tablets, patients, powders, granules, capsules, troches, and the like, which may comprise at least one excipient such as starch, calcium carbonate, It may be prepared by mixing sucrose or lactose or gelatin. In addition to the simple excipients, lubricants such as magnesium styrate talc may also be used.
- suspensions, solutions, emulsions or syrups may be used.
- various excipients such as wetting agents, sweeteners, fragrances, and preservatives may be used. May be included.
- Formulations for parenteral administration may include sterile aqueous solutions, non-aqueous solvents, suspensions, emulsions, lyophilized preparations, suppositories, and the like.
- non-aqueous solvent and the suspension solvent propylene glycol, polyethylene glycol, vegetable oil such as olive oil, injectable ester such as ethyl oleate, and the like can be used.
- base of the suppository witepsol, macrogol, tween 61, cacao butter, laurin butter, glycerol, gelatin and the like can be used.
- One aspect provides a method of preventing, treating or ameliorating joint disease, comprising administering the composition to a subject.
- Another aspect provides a method of producing an extracellular matrix comprising contacting a composition for producing an extracellular matrix from the eukaryotic cell of the present invention with the eukaryotic cell.
- the eukaryotic cell may be isolated from an individual. In one embodiment, the eukaryotic cell may be chondrocytes.
- contacting the eukaryotic cell may comprise co-transfecting or serial-transfecting the composition with the eukaryotic cell.
- a composition of the present invention may comprise co-transfecting or serial-transfecting the composition with the eukaryotic cell.
- microinjection, electroporation, DEAE-dextran treatment, lipofection, nanoparticle-mediated transformation Various methods in the art can be used, such as, but not limited to, injection, protein delivery domain mediated introduction, virus-mediated gene transfer, and PEG-mediated transfection in protozoa.
- contacting the eukaryotic cell comprises culturing the eukaryotic cell in the presence of the composition.
- the culturing step comprises culturing in the presence of a substance that induces cartilage formation.
- the method for producing an extracellular matrix of the present invention further comprises the step of separating the extracellular matrix from the contact product.
- the method of producing the extracellular matrix may comprise contacting the composition for promoting cartilage formation of the present invention with chondrocytes.
- Another aspect provides a method of forming cartilage comprising contacting a composition for promoting cartilage of the present invention with chondrocytes.
- the chondrocytes may be isolated from the individual.
- the chondrocytes may be derived from an individual to which the generated cartilage is transplanted.
- Another aspect includes the steps of culturing eukaryotic cells with increased extracellular matrix production capacity of the present invention to produce ECM; And separating the ECM from the culture.
- the culturing may be culturing in the presence of a substance that induces cartilage formation.
- the substance inducing cartilage may be BMP.
- the composition for promoting the production of extracellular matrix can be injected into a subject in need of the supply of extracellular matrix to prevent, treat and ameliorate diseases including joint diseases, and cells from eukaryotic cells It can be applied to a method for efficiently producing other substrates.
- FIG. 1 is a schematic diagram of a method for manufacturing a MAST4 knockout mouse using the CRISPR / Cas9 system.
- Figure 2A shows the results of confirming the change in the expression amount of each gene in MAST4 knockout mice A and B type by RT-PCR
- Figure 2B shows the protein expression state of MAST4 knocked out mice.
- Figure 3 shows that MAST4 knockout was confirmed in C3H10T1 / 2 cells knocked out by MAST4 using the CRISPR / Cas9 system.
- Figure 4 shows the results of the RT-PCR confirmed the change in the expression level of each gene in MAST4 knocked out C3H10T1 / 2 cells using the CRISPR / Cas9 system.
- Figure 5 shows the results of confirming the change in the expression amount of each gene in the micromass culture (micromass culture) for cartilage formation confirmed by RT-PCR.
- Figure 6 shows the results of confirming the difference in the degree of cartilage differentiation in MAST4 knocked out C3H10T1 / 2 cells using the CRISPR / Cas9 system by Alsian blue staining.
- Figure 7 relates to information of target sequences used to knock out MAST4 of human cells.
- FIG. 8A shows human chondrocytes knocked down MAST4 with siRNA
- FIG. 8B shows the expression level of extracellular matrix factor in human chondrocytes knocked out MAST4 using the CRISPR / Cas system.
- Figure 9 shows the change in the expression level of MAST4 and the resulting extracellular matrix factor after TGF- ⁇ 1 treatment in human cartilage cells.
- Figure 10 confirms the cartilage formation and regeneration effect in the tibia of MAST4 knocked out mice.
- MAST4 knockout mouse was constructed using the CRISPR / Cas9 system.
- pX330-U6-Chimeric_BB-CBh-hSpCas9 (Addgene, # 42230), donated by Dr. Feng Zhang (Cong et al., 2013), to make CRISPR knockout mice, was used as a plasmid capable of expressing Cas9 mRNA and guide RNA.
- MAST4 is a large protein of more than 7 kb, it is designed to be genetically edited for two parts, exon 1 and exon 15.
- the guide RNA sequence targeting exon 1 of MAST4 is 5'-GGAAACTCTGTCGGAGGAAGGGG-3 'and exon 15 Is a 5'-GGCACAAAGAGTCCCGCCAGAGG-3 '.
- the guide RNA sequence was prepared according to the manufacturer's protocol (http://crispr.mit.edu/, Zhang Feng Lab) to prepare oligomers as shown in the MAST4 CRISPR oligomer table below and inserted into the px330 plasmid, exon 1 and 15, respectively. Two plasmids targeted to were cloned.
- mice C57BL / 6J female mice were given 5 IU of Pregnant mare serum gonadotrophin (PMSG; Prospec, cat.no.HOR-272) 2 days before mating, and Humanchorionic gonadotrophin (hCG; Prospec, cat.no) after 47 hours. HOR-250) 5 IU was administered. Embryos were then obtained from fallopian tubes by crossing with C57BL / 6J male mice.
- the microinjection mixture comprising 5 ng / ⁇ l and 10 ng ssDNA donor (ssDNA donor) prepared above was prepared by referring to a standard protocol (Gordon and Ruddle, 1981) of one-cell-stage embryos. Injected into pronuclei. The injected single cell embryos were transferred to fertility ICR mice.
- Phenotypic analysis of born mice was performed on exon 1 and exon 15, and finally two MAST4 knockout mice were obtained. Information on the two types of MAST4 knockout mice, A and B, is shown in FIGS. 2 (5 ' ⁇ 3').
- Type A MAST4 EN (Exon 1 out of 71 bp deletion) (SEQ ID NO: 22) ATGGGGGAGAAAGTTTCCGAGGCGCCTGAGCCCGTGCCCCGGGGCTGCAGCGGACACGGCGCCCGGACCCTAGTCTCTTCGGCGGCAGCCGTGTCCTCGGAGGGCGCTTCCTCAGCGGAGTCATCCTCTGGCTCGGAAACT CTGTCGGAGGAAGGGGAGCCCAGCCGCTTCTCCTGCAGGTCGCAGCCGCCGCGCGCGCCGGGCGGCGCCCT GGGAACCCGGCTACCCGCCGCGTGGGCTCCCGCGCGCGTGGCTCTGGAGCGTGGAGTCCCTACCCTGCCGCTGCCGCACCCGGGAGGAGCGGTGCTGCCGGTGCCAGGTCAGCAGCGCATCCCAAGAGGAGCAGGATGAAGAG Type B MAST4 EN (Exon 1 out of 90 bp Fruiting) (SEQ ID NO: 23) ATGGGGGAAAGTTTCCGAGGCGCCTGAGCCCGTGCCGGGGCTGCAG
- RNA-sequencing was performed on each gene to identify changes in extracellular matrix as a cartilage component in MAST4 knockout mice prepared in Example 1-1.
- the tibia was dissected.
- the incised tibia was immersed in a dish containing DEPC-PBS on ice and cartilage and bone portions of the tibia were separated using a needle using an anatomical microscope.
- Each tissue isolated from each group was soaked in 500 ⁇ l of Trizol (purchased from Invitrogen) to make each sample and RNA was extracted and quantified by Nanodrop (Thermo scientific) according to methods well known in the art.
- RNA-sequencing was performed on terragenetex. Specifically, mRNA was isolated using oligo (dT) from 2 ⁇ g of total RNA extracted from each group of mice. The mRNA was fragmented and synthesized into single-stranded cDNA via random hexamer priming. Using this as a template, secondary strands were synthesized and double-stranded cDNAs were synthesized. End repair was made to make the Blunt-end and A-tailing and Adapter ligation to attach the Adapter. Thereafter, the cDNA library was amplified by using PCR (Polymerase Chain Reaction). 2100 BioAnalyzer was used to check the concentration and size of the final product.
- PCR Polymerase Chain Reaction
- the generated library was finally quantified using KAPA library quantificationkit and then hiseq2500 or less to decode sequence.
- the ratio of base represented by N in the sequence information included 10% or more of the total sequence, or reads having 40% or more of bases less than Q20 were removed, and the average quality was Q20. Filtering was also performed to remove leads below. The entire filtering process was performed by an internally produced program. The filtered sequence was aligned to the species reference genome sequence (hg19) using STAR v2.4.0b (Dobin et al, 2013).
- Expression measurement was calculated using Cufflinksv2.1.1 (Trapnell C. et al, 2010), and the calculated expression value was expressed as fragments read per kilobase of exon per million fragments mapped (FPKM).
- Ensemble 72 was used as the genetic information database, and non-coding gene regions were excluded from the expression-mask option. Multi-read correction and fragment-bias-correct options were used to increase the accuracy of expression measurement, while the default values were used for the other options.
- Col2a1 known as a chondrocyte marker, was identified by fluorescence staining in tibia of mice.
- tibial tissue was obtained from the mouse model of Example 1-1 and fixed overnight at 4 ° C. with 0.01% phosphate-buffered saline (PBS, pH 7.4) at 4 ° C. with 4% paraformaldehyde (PFA, Wako, Osaka, JAPAN). It was.
- the tissue was decalcified with 10% EDTA, embedded in paraffin (Leica Biosystems, Mo., USA) and sectioned to a thickness of 6 mm. Sample slides were stained with hematoxylin and eosin and the tissue sections were incubated with primary antibodies overnight at 4 ° C.
- the primary antibody targets Coll2a1 (Abcam, Cambridge, UK).
- FIG. 10 magnifies a specific portion of the observed sample, with Col2a1 (fluorescent green zone / gray background zone) significantly increased in the tibia of the mouse model knocked out of MAST4.
- TOPRO-3 is a stain of the nuclei of chondrocytes (area marked with red dots / gray dots). Therefore, it can be seen that cartilage formation and regeneration are promoted by MAST4 knockout.
- MAST4 knockout cells were prepared using the CRISPR / Cas9 system to confirm that the extracellular matrix increase phenomenon seen in MAST4 knockout mice was reproduced in vitro.
- C3H / 10T1 / 2 and Clone 8 which are fibroblast cells derived from mice and are capable of differentiating into chondrocytes, were selected for the Department of Medical Genetics, Ajou University School of Medicine. Purchased from Professor's Laboratory (C3H10T1 / 2 cells).
- lentiCRISPR v2 (Plasmid # 52961), pVSVg (AddGene 8454) and psPAX2 (AddGene 12260) were purchased from Addgene and the seller's instructions (lentiCRISPRv2 and lentiGuide oligo cloning) using the oligomers of Table 5 below guide RNA targeting exon 1 of the mouse MAST4 gene (ENSMUSG00000034751) was inserted into the LentiCRISPR v2 plasmid according to the protocol), thereby preparing a plasmid expressing the guide RNA and the Cas9 enzyme simultaneously (control group did not insert guideRNA, but expressed only Cas9). Plasmid was used).
- Oligomer order mMAST4 CRISPR exon 1 sgRNA F (SEQ ID NO: 70) 5'-CACCGTACCCTGCCGCTGCCGCACC-3 ' mMAST4 CRISPR exon 1 sgRNA R (SEQ ID NO: 71) 5'-AAACGGTGCGGCAGCGGCAGGGTAC-3 ' Mouse MAST4 Exon 1 (SEQ ID NO: 72) 5'-ATGGGGGAGAAAGTTTCCGAGGCGCCTGAGCCCGTGCCCCGGGGCTGCAGCGGACACGGCGCCCGGACCCTAGTCTCTTCGGCGGCAGCCGTGTCCTCGGAGGGCGCTTCCTCAGCGGAGTCATCCTCTGGCTCGGAAACTCTGTCGGAGGAAGGGGAGCCCAGCCGCTTCTCCTGCAGGTCGCAGCCGCCGCGCGCCGGGCGGCGCCCTGGGAACCCGGCTACCCGCCGCGTGGGCTCCCGCGCGTGGCTCTGGAGCGTGGAGTCCC TACCCTGCCGCTGCCGCACC CGG
- This method is a CRISPR knockout method based on lentiviral, three plasmids (LentiCRISPR v2 (+ guide RNA) prepared above: guide RNA + Cas9 expressing plasmid, pVSVg: Virus envelop plasmid) were prepared on 293T cells for virus production. , psPAX2: Virus packaging plasmid) was transfected with the reagent polyethyenimine (PEI). After 18 hours, fresh medium was replaced and only the medium was harvested to obtain virus using a 0.45 ⁇ m filter.
- PEI reagent polyethyenimine
- the obtained virus was infected with a 6 well dish seeded with C3H10T / 12, treated with 1 ml of virus + 1 ml of DMEM / FBS + 2 ⁇ l of polybren, and then replaced with fresh DMEM / FBS after 24 hours. After 24 hours, only the infected cells were selected by treatment with puromycin, and passaged up to 40% confluent in 10 cm dishes. Gene editing by CRISPR can occur randomly from cell to cell, thus allowing for single colony selection.
- RT-PCR was performed on each gene in order to confirm the change of the extracellular matrix as a cartilage component in the MAST4 knockout mouse prepared in Example 1-1.
- MAST4 knockout cells were prepared in the same manner as in Example 2-1, and carried out with reference to a conventionally known method (Differentiation and Mineralization of Murine Mesenchymal C3H10T1 / 2 Cells in Micromass Culture, 2010, Rani Roy) for micromass culture. It was. First, 10 ⁇ l of a culture solution containing a total of 10 5 cells in a fibroblast state was placed in the center of each well of a 12 well plate, incubated for 2 hours, and 1 ml of DMEM containing 10% of FBS was added to each well. Each culture was then added with 100ng / ml, 500ng / ml, and 1000ng / ml of BMP2, respectively, for the purpose of inducing cartilage. The culture was then replaced with a new one every three days.
- RNA was isolated on the same day by harvesting the cultures for 0, 3, and 6 days, respectively, based on the day of inoculation on the plate for micromass culture, and Example 1- for each gene.
- RT-PCR was performed as shown in FIG. 3 to determine whether the production of cartilage components was increased.
- Example 3-2 Alcian blue staining was performed to confirm whether the gene overexpression associated with each extracellular matrix component observed in Example 3-2 was increased to a protein unit that is actually obtainable, not to a gene expression unit.
- the plates of cells corresponding to each date were washed twice with PBS and fixed for 15 minutes by adding 1 ml of 4% paraformaldehyde. Then, 1 ml of 1% Alcian blue 8-GX (Sigma-Aldrich, A5268) dissolved in 0.1 N HCl (pH 1.0) was added and stained overnight. Then washed twice with 500ul 0.1N HCl to obtain an image.
- MAST4 siRNA sc-106201; Santa Cruz biotechnology
- siRNA was performed using reverse transfection technology, which simultaneously planted and transfected cells for high transfection efficiency, and the transfection reagent was Lipofectamine® RNAiMAX Transfection Reagent from ThermoFisher SCIENCITFIC. Used. Specifically, 15 nM MAST4 siRNA and 4.5 ⁇ l of Lipofectamine RNAiMax were mixed in 40 ⁇ l of Gibco TM Opti-MEM TM and incubated for 15 minutes. Subsequently, 1.5 x 10 5 cells / well of human primary chondrocytes (*** altered) were added to a 6 well plate (ColI coated plate) with 2 ml of medium without gentamicin (FBS 10%).
- RNA isolated Human primary chondrocytes are DMEM (17-205-CVR Corning), FBS Qualified (USA origin 500mL 26140-079, Gibco), L-Glutamine (200mM) (100x 25030-081, Gibco) and Gentamicin (5 mug / ml) (10 mL 15700-060, Thermofisher) incubated in a flask coated with collagen I (175, Col I Straight Vent 356487, Corning).
- DMEM 17-205-CVR Corning
- FBS Qualified USA origin 500mL 26140-079, Gibco
- L-Glutamine 200mM
- Gentamicin 5 mug / ml
- Knockouts were performed targeting 20nt on the MAST4 genome (sequences for the targets shown in bold in Table 6), specifically # 1, # 3 targeting Exon5, # 2 targeting Exon 8. # 1 and # 3 are made in reverse direction, and # 2 is made in forward direction.
- References to the human MAST4 gene used in the construction of the CRISPR / Cas9 system were based on MAST4 ENSG00000069020 (http://asia.ensembl.org/).
- Targeted Exon sequence information and NGG PAM sequence (grey box) in which CRISPR deletions are generated are specifically disclosed in FIG. 7.
- hMAST4 CR # 1 F (SEQ ID NO: 73) 5'-TAATACGACTCACTATAG GAGTGTGGTCGAGGCAATGC-3 ' hMAST4 CR # 1 R (SEQ ID NO: 74) 5'-TTCTAGCTCTAAAAC GCATTGCCTCGACCACACTC -3 ' hMAST4 CR # 2 F (SEQ ID NO: 75) 5'-TAATACGACTCACTATAG GTAACTCGTCTGGTGTTGGT-3 ' hMAST4 CR # 2 R (SEQ ID NO: 76) 5'-TTCTAGCTCTAAAAC ACCAACACCAGACGAGTTAC -3 ' hMAST4 CR # 3 F (SEQ ID NO: 77) 5'-TAATACGACTCACTATAG AGCAACCGGAAAAGCTTAAT -3 ' hMAST4 CR # 3 R (SEQ ID NO: 78) 5'-TTCTAGCTCTAAAAC ATTAAGCTTTTC
- Example 4- In human cells TGF - of ⁇ 1 MAST4 Inhibit expression and confirm its effects
- TGF- ⁇ 1 was treated to human primary chondrocytes of Example 4-1, and the expression levels thereof were measured using RT-PCR and Western blotting as in Examples 1-2 and 1-3.
- TGF- ⁇ 1 5ng / ml
- MAST4 extracellular matrix factor Able
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Zoology (AREA)
- General Health & Medical Sciences (AREA)
- Biomedical Technology (AREA)
- Wood Science & Technology (AREA)
- Biotechnology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Environmental Sciences (AREA)
- Biophysics (AREA)
- Animal Behavior & Ethology (AREA)
- Plant Pathology (AREA)
- Animal Husbandry (AREA)
- Virology (AREA)
- Immunology (AREA)
- Physics & Mathematics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biodiversity & Conservation Biology (AREA)
- Veterinary Medicine (AREA)
- Microbiology (AREA)
- Medicinal Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Description
MAST4 엑손 1 CRISPR F (서열번호 18) | 5'-caccGGAAACTCTGTCGGAGGAAG-3' |
MAST4 엑손 1 CRISPR R (서열번호 19) | 5'-aaacCTTCCTCCGACAGAGTTTCC-3' |
MAST4 엑손 15 CRISPR F (서열번호 20) | 5'-caccGGCACAAAGAGTCCCGCCAG-3' |
MAST4 엑손 15 CRISPR R (서열번호 21) | 5'-aaacCTGGCGGGACTCTTTGTGCC-3' |
유형 A MAST4 KO (엑손 1 중 71 bp 결실) (서열번호 22) | ATGGGGGAGAAAGTTTCCGAGGCGCCTGAGCCCGTGCCCCGGGGCTGCAGCGGACACGGCGCCCGGACCCTAGTCTCTTCGGCGGCAGCCGTGTCCTCGGAGGGCGCTTCCTCAGCGGAGTCATCCTCTGGCTCGGAAACTCTGTCGGAGGAAGGGGAGCCCAGCCGCTTCTCCTGCAGGTCGCAGCCGCCGCGGCCGCCGGGCGGCGCCCTGGGAACCCGGCTACCCGCCGCGTGGGCTCCCGCGCGCGTGGCTCTGGAGCGTGGAGTCCCTACCCTGCCGCTGCCGCACCCGGGAGGAGCGGTGCTGCCGGTGCCCCAGGTCAGCAGCGCATCCCAAGAGGAGCAGGATGAAGAG |
유형 B MAST4 KO (엑손 1 중 90bp 결실) (서열번호 23) | ATGGGGGAGAAAGTTTCCGAGGCGCCTGAGCCCGTGCCCCGGGGCTGCAGCGGACACGGCGCCCGGACCCTAGTCTCTTCGGCGGCAGCCGTGTCCTCGGAGGGCGCTTCCTCAGCGGAGTCATCCTCTGGCTCGGAAACTCTGTCGGAGGAAGGGGAGCCCAGCCGCTTCTCCTGCAGGTCGCAGCCGCCGCGGCCGCCGGGCGGCGCCCTGGGAACCCGGCTACCCGCCGCGTGGGCTCCCGCGCGCGTGGCTCTGGAGCGTGGAGTCCCTACCCTGCCGCTGCCGCACCCGGGAGGAGCGGTGCTGCCGGTGCCCCAGGTCAGCAGCGCATCCCAAGAGGAGCAGGATGAAGAG |
유형 A MAST4 KO (엑손 15 중 3bp 결실) (서열번호 24) | GGCAGTCTACTTTGTTCGGCACAAAGAG TCCCGC CAG AGGTTTGCCATGAAGAAGAT C AA CAA G CAGAACCTCATCCTTCGGAACCAGATCCAGCAGGCCTTCGTGGAGCGAGACATCCT GACTTTCGCAGAGAACCCCTTTGTGGTCAGCATGTATTGCTCCTTTGAAAC G AGGCGTCA CTTATGCATGGTCATGGAGTATGTAGAAG |
유형 B MAST4 KO (엑손 15 중 13bp 결실) (서열번호 25) | GGCAGTCTACTTTGTTCGGCACAAAG A G TCCCGCCAGAG GTTTGCCATGAAGAAGAT C AA CAA G CAGAACCTCATCCTTCGGAACCAGATCCAGCAGGCCTTCGTGGAGCGAGACATCCT GACTTTCGCAGAGAACCCCTTTGTGGTCAGCATGTATTGCTCCTTTGAAAC G AGGCGTCACTTATGCATGGTCATGGAGTATGTAGAAG |
올리고머 | 서열 |
mMAST4 CRISPR 엑손1 sgRNA F (서열번호 70) | 5'-CACCGTACCCTGCCGCTGCCGCACC-3' |
mMAST4 CRISPR 엑손1 sgRNA R (서열번호 71) | 5'-AAACGGTGCGGCAGCGGCAGGGTAC-3' |
마우스 MAST4 엑손1 (서열번호 72) | 5'-ATGGGGGAGAAAGTTTCCGAGGCGCCTGAGCCCGTGCCCCGGGGCTGCAGCGGACACGGCGCCCGGACCCTAGTCTCTTCGGCGGCAGCCGTGTCCTCGGAGGGCGCTTCCTCAGCGGAGTCATCCTCTGGCTCGGAAACTCTGTCGGAGGAAGGGGAGCCCAGCCGCTTCTCCTGCAGGTCGCAGCCGCCGCGGCCGCCGGGCGGCGCCCTGGGAACCCGGCTACCCGCCGCGTGGGCTCCCGCGCGCGTGGCTCTGGAGCGTGGAGTCCCTACCCTGCCGCTGCCGCACCCGGGAGGAGCGGTGCTGCCGGTGCCCCAGGTCAGCAGCGCATCCCAAGAGGAGCAGGATGAAGAG-3' |
hMAST4 CR#1 F (서열번호 73) | 5'-TAATACGACTCACTATAG GAGTGTGGTCGAGGCAATGC-3' |
hMAST4 CR#1 R (서열번호 74) | 5'-TTCTAGCTCTAAAAC GCATTGCCTCGACCACACTC-3' |
hMAST4 CR#2 F (서열번호 75) | 5'-TAATACGACTCACTATAG GTAACTCGTCTGGTGTTGGT-3' |
hMAST4 CR#2 R (서열번호 76) | 5'-TTCTAGCTCTAAAAC ACCAACACCAGACGAGTTAC-3' |
hMAST4 CR#3 F (서열번호 77) | 5'-TAATACGACTCACTATAG AGCAACCGGAAAAGCTTAAT-3' |
hMAST4 CR#3 R (서열번호 78) | 5'-TTCTAGCTCTAAAAC ATTAAGCTTTTCCGGTTGCT-3' |
HumanAcanRT Forward (336) (서열번호 82) | 5'-gaatcaactgctgcagacca-3' |
HumanAcan RT Reverse (336) (서열번호 83) | 5'-gtgccagatcatcaccacac-3' |
HumanCol9a1RT Forward (467) (서열번호 84) | 5'-CGTGGATTTCCAGGCCGTGG-3' |
HumanCol9a1RT Reverse (467) (서열번호 85) | 5'-TCGCTGTCCTTGATCACCAG-3' |
HumanGapdhRT Forward (156) (서열번호 86) | 5'-TGGCAAAGTGGAGATTGTTGCC-3' |
HumanGapdhRT Reverse (156) (서열번호 87) | 5'-AAGATGGTGATGGGCTTCCCG-3' |
Claims (20)
- MAST4(Microtubule Associated Serine/Threonine Kinase Family Member 4) 단백질 또는 이의 단편에 특이적으로 결합할 수 있는 화합물, 또는 상기 MAST4 단백질 또는 이의 단편을 코딩하는 핵산에 특이적으로 결합할 수 있는 화합물을 포함하는, 진핵세포에서 세포외 기질의 생산을 촉진하기 위한 조성물.
- 청구항 1에 있어서, 상기 MAST4 단백질은 서열번호 1 내지 7 및 15 중 어느 하나의 아미노산 서열을 포함하는 것이고, 상기 MAST4 단백질을 코딩하는 핵산은 서열번호 8 내지 14 및 16 중 어느 하나의 폴리뉴클레오티드 서열을 포함하는 것인 조성물.
- 청구항 1에 있어서, 상기 MAST4 단백질 또는 이의 단편에 특이적으로 결합할 수 있는 화합물, 또는 상기 MAST4 단백질 또는 이의 단편을 코딩하는 핵산에 특이적으로 결합할 수 있는 화합물은 상기 MAST4 단백질의 활성 또는 발현을 저해하는 화학적으로 합성된 화합물, 폴리펩티드, 폴리뉴클레오티드 또는 이들의 조합인 것인 조성물.
- 청구항 3에 있어서, 상기 폴리펩티드는 항체, 또는 이의 항원 결합 단편인 것인 조성물.
- 청구항 1에 있어서, 상기 MAST4 단백질 또는 이의 단편을 코딩하는 핵산에 특이적으로 결합할 수 있는 화합물은 상기 MAST4 단백질 또는 이의 단편을 코딩하는 핵산에 특이적인 miRNA(microRNA), siRNA(small interfering RNA), shRNA(short hairpin RNA), Piwi-상호작용 RNA(Piwi-interacting RNA; piRNA), snRNA(small nuclear RNA), 안티센스 올리고뉴클레오티드 또는 이들의 조합인 것인 조성물.
- 청구항 1에 있어서, 상기 MAST4 단백질 또는 이의 단편을 코딩하는 핵산에 특이적으로 결합할 수 있는 화합물은 상기 MAST4 단백질 또는 이의 단편을 코딩하는 핵산에 특이적인 가이드 RNA (guide RNA)를 포함하는 CRISPR-Cas인 것인 조성물.
- 청구항 6에 있어서, 상기 가이드 RNA는 상기 MAST4 단백질 또는 이의 단편을 코딩하는 핵산에 특이적인 crRNA(CRISPR RNA) 및 tracrRNA (transactivating crRNA)를 포함하는 이중RNA (dualRNA), 또는 상기 crRNA 및 tracrRNA의 부분을 포함하고 상기 MAST4 단백질 또는 이의 단편을 코딩하는 핵산과 혼성화하는 단일-사슬 가이드 RNA (single strand guideRNA) 것인 조성물.
- 청구항 1에 있어서, 상기 진핵세포는 섬유아세포(fibroblast) 또는 연골세포(chondrocyte)인 것인 조성물.
- 청구항 1에서, 상기 진핵세포로부터 연골형성(chondrogenesis)을 촉진하기 위한 것인 조성물.
- 청구항 1에 있어서, 관절 질환의 예방, 치료 또는 증상의 개선을 위한 것인 조성물.
- 청구항 9에 있어서, 상기 연골형성 촉진은 연골재생을 유도하기 위한 것인 조성물.
- 청구항 1에 있어서, 조직 재생 또는 노화를 방지하는데 사용하기 위한 조성물.
- 청구항 1에 있어서, 상기 조성물은 TGF-β1을 더 포함하는 것인 조성물.
- 청구항 1의 조성물을 개체에 투여하는 단계를 포함하는, 관절 질환의 예방, 치료 또는 개선시키는 방법.
- 청구항 1의 진핵세포로부터 세포외 기질 생산을 촉진하기 위한 조성물을 진핵세포와 접촉시키는 단계를 포함하는 진핵세포로부터 세포외 기질 생산하는 방법.
- 청구항 15에 있어서, 상기 진핵세포는 개체로부터 분리된 것인 방법.
- 청구항 15에 있어서, 상기 진핵 세포와 접촉시키는 단계는 상기 조성물의 존재하에서 상기 진핵세포를 배양하는 단계를 포함하는 것인 방법.
- 청구항 17에 있어서, 상기 배양하는 단계는 연골형성을 유도하는 물질의 존재하에서 배양하는 것인 방법.
- 청구항 15에 있어서, 접촉 산물로부터 세포외 기질을 분리하는 단계를 더 포함하는 세포외 기질을 생산하는 방법.
- 청구항 15에 있어서, 상기 진핵세포는 연골세포인 것인 세포외 기질을 생산하는 방법.
Priority Applications (9)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2019571194A JP7154238B2 (ja) | 2017-03-08 | 2018-03-08 | Mast4遺伝子を利用した細胞外基質生産用組成物及びその製造方法 |
AU2018231559A AU2018231559A1 (en) | 2017-03-08 | 2018-03-08 | Extracellular matrix-producing composition using MAST4 gene and preparation method therefor |
EP18764604.7A EP3594324A4 (en) | 2017-03-08 | 2018-03-08 | EXTRACELLULAR MATRIX-PRODUCING COMPOSITION WITH MAST4-GEN AND MANUFACTURING METHOD FOR IT |
CA3055729A CA3055729A1 (en) | 2017-03-08 | 2018-03-08 | Extracellular matrix-producing composition using mast4 gene and preparation method therefor |
CN201880030519.0A CN110612348B (zh) | 2017-03-08 | 2018-03-08 | 用于使用mast4基因产生细胞外基质的组合物及其制备方法 |
US16/492,477 US11180573B2 (en) | 2017-03-08 | 2018-03-08 | Extracellular matrix-producing composition using MAST4 gene and preparation method therefor |
US17/494,765 US20220220221A1 (en) | 2017-03-08 | 2021-10-05 | Extracellular matrix-producing composition using mast4 gene and preparation method therefor |
JP2022159928A JP7498239B2 (ja) | 2017-03-08 | 2022-10-04 | Mast4遺伝子を利用した細胞外基質生産用組成物及びその製造方法 |
AU2023222944A AU2023222944A1 (en) | 2017-03-08 | 2023-08-31 | Extracellular matrix-producing composition using MAST4 gene and preparation method therefor |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR10-2017-0029607 | 2017-03-08 | ||
KR20170029607 | 2017-03-08 | ||
KR10-2018-0027111 | 2018-03-07 | ||
KR1020180027111A KR102588627B1 (ko) | 2017-03-08 | 2018-03-07 | Mast4 유전자를 이용한 세포외 기질 생산용 조성물 및 그 제조방법 |
Related Child Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US16/492,477 A-371-Of-International US11180573B2 (en) | 2017-03-08 | 2018-03-08 | Extracellular matrix-producing composition using MAST4 gene and preparation method therefor |
US17/494,765 Continuation US20220220221A1 (en) | 2017-03-08 | 2021-10-05 | Extracellular matrix-producing composition using mast4 gene and preparation method therefor |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2018164507A2 true WO2018164507A2 (ko) | 2018-09-13 |
WO2018164507A3 WO2018164507A3 (ko) | 2019-04-11 |
Family
ID=63447864
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/KR2018/002763 WO2018164507A2 (ko) | 2017-03-08 | 2018-03-08 | Mast4 유전자를 이용한 세포외 기질 생산용 조성물 및 그 제조방법 |
Country Status (1)
Country | Link |
---|---|
WO (1) | WO2018164507A2 (ko) |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN105636614A (zh) | 2013-09-09 | 2016-06-01 | 菲格内有限责任公司 | 用于软骨细胞或软骨型细胞再生的基因治疗 |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
MX353186B (es) * | 2009-09-03 | 2018-01-05 | Genentech Inc | Metodos para el tratamiento, diagnosis y monitoreo de artritis reumatoide. |
KR102039311B1 (ko) * | 2012-09-07 | 2019-11-04 | 주식회사 마크로젠 | Axl을 포함하는 융합 단백질 및 이를 포함하는 암 진단용 조성물 |
EP3307728A4 (en) * | 2015-06-12 | 2019-07-17 | Dana Farber Cancer Institute, Inc. | ASSOCIATION THERAPY USING TRANSCRIPTION INHIBITORS AND KINASE INHIBITORS |
-
2018
- 2018-03-08 WO PCT/KR2018/002763 patent/WO2018164507A2/ko unknown
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN105636614A (zh) | 2013-09-09 | 2016-06-01 | 菲格内有限责任公司 | 用于软骨细胞或软骨型细胞再生的基因治疗 |
Non-Patent Citations (2)
Title |
---|
BMC GENOMICS, vol. 8, 2007, pages 165 |
See also references of EP3594324A4 |
Also Published As
Publication number | Publication date |
---|---|
WO2018164507A3 (ko) | 2019-04-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Song et al. | Regulation and function of SOX9 during cartilage development and regeneration | |
WO2018030608A1 (ko) | Cas9 단백질 및 가이드 RNA의 혼성체를 함유하는 나노 리포좀 전달체 조성물 | |
JP2021182934A (ja) | アルファ1アンチトリプシン欠乏症の治療のための材料および方法 | |
JP2020182452A (ja) | 多能性幹細胞を所望の細胞型へ分化する方法 | |
WO2019050071A1 (ko) | 엑소좀 또는 엑소좀 유래 리보핵산을 포함하는 간섬유증 예방 또는 치료용 조성물 | |
KR102201417B1 (ko) | 도파민 신경세포의 분리방법 및 이를 이용하여 분리된 도파민 신경세포를 포함하는 파킨슨병 치료용 약제학적 조성물 | |
JP2022522650A (ja) | Crispr-casエフェクターポリペプチド及びその使用方法 | |
US20220220221A1 (en) | Extracellular matrix-producing composition using mast4 gene and preparation method therefor | |
US20180147256A1 (en) | Means and methods for treating facioscapulohumeral muscular dystrophy (fshd). | |
US20120003186A1 (en) | Method for dedifferentiating adipose tissue stromal cells | |
WO2018030630A1 (ko) | Sox 유전자가 이입된 비바이러스성 미니써클 벡터 및 이의 제조방법 | |
Guo et al. | XBP 1S, a BMP 2‐inducible transcription factor, accelerates endochondral bone growth by activating GEP growth factor | |
JP2022545462A (ja) | Crispr/cas9ベースの転写活性化因子による骨格筋芽細胞前駆細胞系譜特定 | |
WO2020017914A1 (ko) | Setdb1 또는 이의 저해제를 포함하는 암세포의 분열 또는 분화 조절용 조성물 | |
WO2018164507A2 (ko) | Mast4 유전자를 이용한 세포외 기질 생산용 조성물 및 그 제조방법 | |
CA3096274A1 (en) | Compositions and methods for somatic cell reprogramming and modulating imprinting | |
WO2015088162A1 (ko) | 줄기세포로부터 연골세포로의 분화 촉진용 조성물 | |
TW201629227A (zh) | 新穎治療用抗癌藥的製造與使用 | |
JP7498239B2 (ja) | Mast4遺伝子を利用した細胞外基質生産用組成物及びその製造方法 | |
KR102089088B1 (ko) | 혈액 응고인자 ⅷ의 교정용 조성물 및 이를 이용한 방법 | |
KR101642202B1 (ko) | Klf10 발현 억제제를 포함하는 연골세포 분화 촉진 또는 연골질환 치료용 조성물, 및 이를 이용한 연골분화 촉진 방법 | |
KR20120134360A (ko) | 세포의 역분화 증진용 조성물 및 이를 이용한 유도 만능 줄기세포의 제조방법 | |
WO2020122534A1 (ko) | Snai1의 발현을 억제하는 비대칭 sirna | |
CN115054612B (zh) | 一种可用于促进骨形成的增强子及其应用 | |
Zhou et al. | Treating congenital megacolon by transplanting GDNF and GFRα-1 double genetically modified rat bone marrow mesenchymal stem cells |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
ENP | Entry into the national phase |
Ref document number: 3055729 Country of ref document: CA Ref document number: 2019571194 Country of ref document: JP Kind code of ref document: A |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
ENP | Entry into the national phase |
Ref document number: 2018764604 Country of ref document: EP Effective date: 20191008 |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 18764604 Country of ref document: EP Kind code of ref document: A2 |
|
ENP | Entry into the national phase |
Ref document number: 2018231559 Country of ref document: AU Date of ref document: 20180308 Kind code of ref document: A |